Sera Prognostics (SERA) Debt to Equity (2020)

Sera Prognostics (SERA) reported Debt to Equity of -$0.04 for Q4 2020.

Sera Prognostics (SERA) Debt to Equity (2020) Analysis & Trends

Sera Prognostics has reported Debt to Equity for 1 years, with the latest figure at -$0.04 in Q4 2020.

For the quarter ending Q4 2020, Debt to Equity changed N/A year-over-year to -$0.04; the trailing twelve-month figure through Dec 2020 stood at -$0.04 (changed N/A YoY), and the FY2020 full-year result was -$0.04, changed N/A from the prior year.
Debt to Equity for Q4 2020 stood at -$0.04.
The five-year high for Debt to Equity was -$0.04 in Q4 2020, with the low at -$0.04 in Q4 2020.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt/Equity (Qtr)
1	Abbott Laboratories	152.92 Bn	146.27 Bn	6.27 Bn	0.65
2	Stryker	119.50 Bn	116.62 Bn	3.81 Bn	0.64
3	Medtronic	102.71 Bn	94.54 Bn	5.76 Bn	0.57
4	Boston Scientific	69.72 Bn	68.51 Bn	3.61 Bn	0.42
5	Edwards Lifesciences	49.24 Bn	45.57 Bn	1.29 Bn	0.06
6	GE HealthCare Technologies	29.74 Bn	27.67 Bn	1.98 Bn	0.95
7	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn	0.71
8	Dexcom	28.96 Bn	27.84 Bn	750.30 Mn	-
9	Steris	20.31 Bn	19.88 Bn	697.10 Mn	0.27
10	Sera Prognostics	100.52 Mn	100.52 Mn	-28,000.00	-

Historic Data

Download Data

Date	Value
Dec 31, 2020	-0.04